期刊
BLOOD RESEARCH
卷 56, 期 2, 页码 102-107出版社
KOREAN SOC HEMATOLOGY
DOI: 10.5045/br.2021.2021086
关键词
5q deletion syndrome; Myelodysplastic syndrome; Lenalidomide; Anemia
类别
In a nationwide retrospective analysis in Korea, lenalidomide was effective and tolerable for del(5q) MDS patients with transfusion-dependent anemia, with RBC transfusion independence achieved in 67.9% of evaluable patients. Female sex and thrombocytopenia were associated with better outcomes. The most common non-hematologic toxicities were pruritus, fatigue, and rashes, with dose reduction required for most responders.
Background To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea. Methods Patients aged >= 19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed. Results A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades >= 3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%). Conclusion Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据